Taysha Gene Therapies (TSHA) Stock
Clinical stage biotech developing gene therapies for rare diseases. Here's the price, business snapshot, and what's worth knowing about Taysha Gene Therapies in June 2026.
Taysha Gene Therapies Inc (TSHA) is a clinical-stage biotechnology company developing gene therapies for neurological and rare genetic disorders. With a market capitalisation of about $1.40 billion, Taysha focuses on delivering adeno-associated virus (AAV)тАСbased treatments designed to address root causes rather than symptoms. Investors should note the company is largely driven by clinical trial progress, regulatory milestones and potential partnerships or licensing deals. Like many geneтАСtherapy developers, Taysha faces binary outcome risk from trial results, significant research and development costs, and potential dilution if additional capital is required. That said, success in trials or a favourable regulatory path could meaningfully reтАСrate the business. This summary is educational only and not personal financial advice; investors should consider their risk tolerance, investment horizon and seek independent advice before acting.
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying Taysha Gene Therapies stock with a target price of $10.79, indicating potential growth.
Financial Health
Taysha Gene Therapies is generating modest revenue and cash flow, but has room for improvement.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Discover More Opportunities
ACADIA PHARMACEUTICALS INC
ACADIA Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of treatments for central nervous system disorders.
ADAPTIVE BIOTECHNOLOGIES CORP
Adaptive Biotechnologies Corporation is a commercial-stage company. The Company focuses on the field of immune medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its immune medicine platform applies its technologies to read the genetic code of a patient's immune system. It operates through two segments, which include Minimal Residual Disease (MRD) and Immune Medicine. The MRD business focuses on the use of its sensitive, next-generation sequencing (NGS) assay to measure MRD in patients with hematologic malignancies. Its MRD business is comprised of its clonoSEQ clinical diagnostic testing service, offered to clinicians. Its Immune Medicine business focuses on immune-repertoire sequencing, target antigen discovery, data licensing and TCR-antigen prediction models in the identification, validation, development and adoption of products and services.
ABCELLERA BIOLOGICS INC
AbCellera Biologics Inc is a biotechnology company that provides technology to discover and develop novel fully human monoclonal antibodies.
Baskets Featuring TSHA
Investment Opportunities in RNA Therapeutics Explained
Eli Lilly's $2.4 billion acquisition of Orna Therapeutics signals a major bet on circular RNA and in vivo cell engineering. This theme focuses on the broader ecosystem of companies developing the next-generation platforms and delivery technologies essential for advancing genetic medicine.
Published: 10 February 2026
Explore BasketGene Therapy's Regulatory Tailwind
Sarepta Therapeutics' stock surged after the FDA re-approved its gene therapy for muscular dystrophy, signaling a positive turn for the industry. This development creates a potential tailwind for other biotech companies specializing in novel treatments for rare genetic diseases.
Published: 30 July 2025
Explore BasketGene Therapy's Competitive Shift
The European Medicines Agency's recent rejection of Sarepta Therapeutics' gene therapy creates a potential opening for its competitors. This theme focuses on the biopharmaceutical companies that stand to benefit from this regulatory hurdle in the Duchenne muscular dystrophy market.
Published: 25 July 2025
Explore BasketWhy YouтАЩll Want to Watch This Stock
Clinical programmes progress
TayshaтАЩs value largely depends on trial outcomes and regulatory milestones, which can create opportunity but also binary downside risks.
CatalystтАСdriven moves
Share price may react strongly to news such as trial readouts, partnerships or licensing deals, though performance can be volatile.
Manufacturing & access
Scaling geneтАСtherapy manufacturing and securing market access are crucial for longтАСterm value; these areas carry technical and commercial risks.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
